Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Forecasted to Earn Q2 2025 Earnings of ($1.62) Per Share

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Investment analysts at Zacks Research boosted their Q2 2025 EPS estimates for Agios Pharmaceuticals in a research note issued to investors on Wednesday, May 1st. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will earn ($1.62) per share for the quarter, up from their prior estimate of ($1.65). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($5.27) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q3 2025 earnings at ($1.56) EPS, Q4 2025 earnings at ($1.65) EPS, FY2025 earnings at ($6.49) EPS, Q1 2026 earnings at ($1.50) EPS and FY2026 earnings at ($5.31) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.64) by $0.19. Agios Pharmaceuticals had a negative return on equity of 39.74% and a negative net margin of 1,199.26%. The company had revenue of $8.19 million during the quarter, compared to analysts’ expectations of $8.37 million. During the same quarter in the prior year, the firm posted ($1.47) EPS. Agios Pharmaceuticals’s quarterly revenue was up 46.0% compared to the same quarter last year.

A number of other equities analysts have also recently weighed in on the stock. Royal Bank of Canada reduced their price objective on shares of Agios Pharmaceuticals from $43.00 to $42.00 and set an “outperform” rating for the company in a research report on Friday, February 16th. JPMorgan Chase & Co. lowered their target price on shares of Agios Pharmaceuticals from $31.00 to $30.00 and set a “neutral” rating on the stock in a research note on Friday, February 23rd. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, April 9th. Finally, The Goldman Sachs Group boosted their price target on shares of Agios Pharmaceuticals from $29.00 to $33.00 and gave the stock a “neutral” rating in a research report on Friday. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $35.00.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ:AGIO opened at $34.54 on Monday. The business’s 50 day moving average price is $30.61 and its 200-day moving average price is $25.68. Agios Pharmaceuticals has a 1 year low of $19.80 and a 1 year high of $35.50. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of -5.47 and a beta of 0.81.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Agios Pharmaceuticals by 0.8% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 39,248 shares of the biopharmaceutical company’s stock valued at $1,148,000 after acquiring an additional 314 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in Agios Pharmaceuticals by 96.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,429 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 700 shares in the last quarter. Teacher Retirement System of Texas boosted its stake in shares of Agios Pharmaceuticals by 5.3% in the 3rd quarter. Teacher Retirement System of Texas now owns 15,770 shares of the biopharmaceutical company’s stock valued at $390,000 after buying an additional 788 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Agios Pharmaceuticals by 9.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,444 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 942 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Agios Pharmaceuticals by 1.2% during the third quarter. Rhumbline Advisers now owns 102,122 shares of the biopharmaceutical company’s stock worth $2,528,000 after buying an additional 1,240 shares during the period.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, CEO Brian Goff sold 4,156 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $32.57, for a total transaction of $135,360.92. Following the completion of the sale, the chief executive officer now directly owns 53,780 shares of the company’s stock, valued at approximately $1,751,614.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Brian Goff sold 4,156 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $32.57, for a total value of $135,360.92. Following the completion of the sale, the chief executive officer now owns 53,780 shares in the company, valued at approximately $1,751,614.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider James William Burns sold 2,642 shares of the company’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $32.57, for a total value of $86,049.94. Following the transaction, the insider now owns 34,518 shares in the company, valued at $1,124,251.26. The disclosure for this sale can be found here. Insiders sold a total of 16,035 shares of company stock worth $475,277 in the last three months. 4.24% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.